ELAN FRAUD INVESTIGATION: Elanco (NYSE:ELAN) Shareholders

NEW YORK, July 29, 2024 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation of Elanco Animal Health Incorporated (NYSE:ELAN) for possible violations of the federal securities laws.

If you have invested in Elanco, we recommend that you For further information please visit https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated.

Why did Elanco’s share price fall?

Elanco develops products to treat animal diseases. Two of the most important treatments in the company’s development pipeline are currently under review by the U.S. Food and Drug Administration (“FDA”). The treatments are Zenrelia, a drug for a type of dermatitis in dogs, and Credelio Quattro, an oral broad-spectrum parasiticide for fleas, ticks and internal parasites.
Regarding these treatments, the company stated that the FDA “has all the data necessary to complete its review. All technical sections, including the label, are expected to be approved before the end of June (2024).” However, on June 27, 2024, Elanco announced that it expected the FDA would not approve either drug in June 2024 and that Zenrelia would come with a boxed safety warning.

As a result of this news, Elanco’s stock price declined over 21%, from $17.97 per share on June 26, 2024 to $14.27 per share on June 27, 2024. BFA Law is investigating whether Elanco and certain of its executives made materially false and/or misleading statements to investors in connection with the FDA approval of its drugs.

Click here if you have suffered losses: https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated.

What can you do?

If you have invested in Elanco Animal Health Incorporated (NYSE: ELAN), you may have legal options available to you. We encourage you to provide your information to the company. All representations are made on a contingency basis, with no costs to you. Shareholders are not responsible for court or litigation costs. The company will seek court approval for any fees and costs.

Send your information to:

https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated

Or contact us:
Ross Shikowitz
[email protected]
212-789-3619

Why Bleichmar Fonti & Auld LLP?

Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in class actions and shareholder litigation. It was named a Top 5 Plaintiffs Firm for 2023 by ISS SCAS and its lawyers have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Recent notable successes include BFA recovering over $900 million in value from the board of Tesla, Inc. (subject to court approval) and $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, visit https://www.bfalaw.com.

https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated

Attorney advertising. Past results do not guarantee future results.